In this week's blog, Dr. Kert Viele discusses his thoughts on the RAR literature and the current state of RAR in practical clinical trials. He focuses on general principles that have emerged in the literature, the nuts and bolts of constructing and tuning RAR designs, and operational issues.

In this episode of "In the Interim…", Dr. Scott Berry and Dr. Kert Viele examine response-adaptive randomization (RAR) in clinical trials, dissecting its statistical rationale, common criticisms, and implementation challenges.

In this episode of "In the Interim…", Dr. Scott Berry explores the origins of REMAP-CAP with Prof. Steve Webb, former chair of the REMAP-CAP International Trial Steering Committee.

Longitudinal modeling and predictive modeling are the foundation of learning efficiently in adaptive clinical trials, allowing real-time learning from early data. Bayesian models enable faster, more informed decisions even when primary endpoints are distant.

In this episode of "In the Interim…", Dr. Scott Berry explores the challenge of protracted endpoint timelines in adaptive clinical trials and the statistical strategies used to increase the rate of actionable information gain.

In this episode of "In the Interim…", Dr. Scott Berry is joined by Dr. Will Meurer, professor of Emergency Medicine and Neurology at the University of Michigan, for an in-depth analysis of the ICECAP trial’s adaptive Bayesian design.